BMY Bristol Myers Squibb
NYSE · SEC CIK 14272 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $2.29M 3 sales by 3 insiders
- Filings on record
- 369 since 2021-07-01, latest 2026-09-10 16:37
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Elkins David V | EVP, CFO | — | $1.85M |
| Massacesi Cristian | EVP, Chief Med Offr, Head of Dev | — | $403.5K |
| Holzer Phil M | SVP, Ctrl | — | $33.8K |
| Short Bartie Wendy | EVP, Corp. Affairs | — | — |
| Hoch Lynelle | Pres, Cell Therapy Org | — | — |
| Poole Ahn Amanda | EVP, CHRO | — | — |
| Gallman Cari | EVP, GC | — | — |
| Lenkowsky Adam | EVP, Chief Commercial Off | — | — |
| Shanahan Karin | EVP, Chief Supply Chain, Ops | — | — |
| Meyers Gregory Scott | EVP, Chief Digital, Tech Off | — | — |
Transactions 333
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-28 | 2022-02-24 | BMY | Caforio Giovanni | CEO, Board COB, Dir | S - Sale | $67.00 | -30.0K | 453.5K | -6% | -$2.01M | |
| D | 2022-02-08 | 2022-02-04 | BMY | VESSEY RUPERT | EVP, Research, Early Dev | M - OptEx | $0.00 | +3,593 | 57.5K | +7% | $0 |
| D | 2022-02-08 | 2022-02-04 | BMY | VESSEY RUPERT | EVP, Research, Early Dev | F - Tax | $64.99 | -1,312 | 56.2K | -2% | -$85.3K |
| D | 2022-01-04 | 2021-12-31 | BMY | VESSEY RUPERT | EVP, Research, Early Dev | F - Tax | $62.35 | -23.0K | 54.0K | -30% | -$1.44M |
| D | 2022-01-04 | 2021-12-31 | BMY | VESSEY RUPERT | EVP, Research, Early Dev | M - OptEx | $0.00 | +45.0K | 77.0K | +141% | $0 |
| D | 2022-01-04 | 2021-12-31 | BMY | Elkins David V | EVP, CFO | M - OptEx | $0.00 | +47.4K | 131.7K | +56% | $0 |
| D | 2022-01-04 | 2021-12-31 | BMY | Elkins David V | EVP, CFO | F - Tax | $62.35 | -24.2K | 107.5K | -18% | -$1.51M |
| M | 2021-12-17 | 2021-12-16 | BMY | VESSEY RUPERT | EVP, Research, Early Dev | S - Sale | $61.99 | -19.3K | 32.0K | -38% | -$1.20M |
| D | 2021-12-06 | 2021-12-02 | BMY | Elkins David V | EVP, CFO | F - Tax | $55.41 | -4,498 | 84.3K | -5% | -$249.2K |
| D | 2021-12-06 | 2021-12-02 | BMY | Elkins David V | EVP, CFO | M - OptEx | $0.00 | +8,792 | 88.8K | +11% | $0 |
| D | 2021-12-06 | 2021-12-02 | BMY | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Off | M - OptEx | $0.00 | +2,638 | 39.9K | +7% | $0 |
| D | 2021-12-06 | 2021-12-02 | BMY | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Off | F - Tax | $55.41 | -1,350 | 38.5K | -3% | -$74.8K |
| D | 2021-12-06 | 2021-12-02 | BMY | VESSEY RUPERT | EVP, Research, Early Dev | M - OptEx | $0.00 | +8,792 | 55.8K | +19% | $0 |
| D | 2021-12-06 | 2021-12-02 | BMY | VESSEY RUPERT | EVP, Research, Early Dev | F - Tax | $55.41 | -4,498 | 51.3K | -8% | -$249.2K |
| MI | 2021-11-24 | 2021-11-22+ | BMY | von Autenried Paul | EVP, CIO | S - Sale | $57.18 | -51.1K | 80.9K | -39% | -$2.92M |
| 2021-09-22 | 2021-09-20 | BMY | Caforio Giovanni | CEO, Board COB, Dir | S - Sale | $60.64 | -25.0K | 484.0K | -5% | -$1.52M | |
| DM | 2021-08-16 | 2021-08-12 | BMY | Elkins David V | EVP, CFO | S - Sale+OE | $66.95 | -99.7K | 80.0K | -55% | -$6.67M |
| DM | 2021-08-16 | 2021-08-12 | BMY | Elkins David V | EVP, CFO | M - OptEx | $48.49 | +70.0K | 80.0K | +699% | +$3.39M |
| 2021-08-04 | 2021-08-03 | BMY | Powell Ann | EVP, Chief Human Resources | S - Sale | $68.57 | -23.3K | 47.6K | -33% | -$1.60M | |
| 2021-08-04 | 2021-08-02 | BMY | Caforio Giovanni | COB, CEO, Dir | S - Sale | $68.58 | -20.0K | 509.0K | -4% | -$1.37M | |
| I | 2021-08-03 | 2021-07-30 | BMY | von Autenried Paul | EVP, CIO | G - Gift | $0.00 | +114.7K | 114.7K | New | $0 |
| 2021-08-03 | 2021-07-30 | BMY | von Autenried Paul | EVP, CIO | G - Gift | $0.00 | -114.7K | 0 | -100% | $0 | |
| 2021-08-03 | 2021-07-30 | BMY | von Autenried Paul | EVP, CIO | S - Sale | $68.06 | -25.0K | 114.7K | -18% | -$1.70M | |
| DM | 2021-08-03 | 2021-07-30 | BMY | VESSEY RUPERT | EVP, Research, Early Dev | M - OptEx | $58.49 | +151.0K | 42.5K | New | +$8.83M |
| DM | 2021-08-03 | 2021-07-30 | BMY | VESSEY RUPERT | EVP, Research, Early Dev | S - Sale+OE | $68.07 | -158.4K | 36.6K | -81% | -$10.78M |
| 2021-08-03 | 2021-07-30 | BMY | LEUNG SANDRA | EVP, GC | S - Sale | $68.04 | -29.4K | 340.0K | -8% | -$2.00M | |
| D | 2021-08-03 | 2021-08-01 | BMY | Elkins David V | EVP, CFO | M - OptEx | $0.00 | +46.4K | 133.4K | +53% | $0 |
| D | 2021-08-03 | 2021-08-01 | BMY | Elkins David V | EVP, CFO | F - Tax | $67.87 | -23.7K | 109.7K | -18% | -$1.61M |
| 2021-08-03 | 2021-07-30 | BMY | Dubow Adam | SVP, ChiefCompliance, EthicsOff | S - Sale | $67.90 | -2,466 | 13.8K | -15% | -$167.4K | |
| D | 2021-07-06 | 2021-07-01 | BMY | Santiago Karen Murphy | SVP, Ctrl | M - OptEx | $0.00 | +1,069 | 15.0K | +8% | $0 |
| D | 2021-07-06 | 2021-07-01 | BMY | Santiago Karen Murphy | SVP, Ctrl | F - Tax | $66.56 | -547 | 14.5K | -4% | -$36.4K |
| D | 2021-07-06 | 2021-07-01 | BMY | Hirawat Samit | EVP, Chief Med.Offr, Drug Dev | F - Tax | $66.56 | -4,786 | 11.8K | -29% | -$318.6K |
| D | 2021-07-06 | 2021-07-01 | BMY | Hirawat Samit | EVP, Chief Med.Offr, Drug Dev | M - OptEx | $0.00 | +9,356 | 16.5K | +130% | $0 |
Purchase Sale Sale after option exercise All abbreviations